APA (7th ed.) Citation

Blauvelt, A., Papp, K., Trivedi, M., Barragan, C., Chow, V., Mytych, D., . . . Franklin, J. (2025). Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: A randomized double-blinded active-controlled comparative clinical study over 52 weeks. British Journal of Dermatology, 192(5), 826. https://doi.org/10.1093/bjd/ljae402

Chicago Style (17th ed.) Citation

Blauvelt, Andrew, Kim Papp, Mona Trivedi, Carolina Barragan, Vincent Chow, Daniel T Mytych, Paul Yamauchi, Jeff Crowley, and Janet Franklin. "Efficacy and Safety of the Ustekinumab Biosimilar ABP 654 in Patients with Moderate-to-severe Plaque Psoriasis: A randomized Double-blinded Active-controlled Comparative Clinical Study over 52 Weeks." British Journal of Dermatology 192, no. 5 (2025): 826. https://doi.org/10.1093/bjd/ljae402.

MLA (9th ed.) Citation

Blauvelt, Andrew, et al. "Efficacy and Safety of the Ustekinumab Biosimilar ABP 654 in Patients with Moderate-to-severe Plaque Psoriasis: A randomized Double-blinded Active-controlled Comparative Clinical Study over 52 Weeks." British Journal of Dermatology, vol. 192, no. 5, 2025, p. 826, https://doi.org/10.1093/bjd/ljae402.